QIAGEN (QGEN) Announces CE Mark on Next Generation Molecular Diagnostic for KRAS Analysis
Tweet Send to a Friend
QIAGEN (NASDAQ: QGEN) announced the official launch of its next-generation CE-labelled assay for KRAS testing in colorectal cancer patients. In ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
